A website to provide support for people who have or have had any type of cancer, for their caregivers and for their family members.
Results 1 to 2 of 2

Thread: NICE Guidance Prostate cancer: diagnosis and management (June 2019)

  1. #1

    NICE Guidance Prostate cancer: diagnosis and management (June 2019)

    A revision of the NICE Guidance – Prostate cancer: diagnosis and management was published yesterday. The Full Text is available online. Here is an editorial about it and a link to it. (NICE is a British organization.)

    NICE guidelines on prostate cancer 2019 [2019, Editorial]

    The much‐anticipated National Institute for Health and Care Excellence (NICE) Guidelines are finally published 1 after a period of consultation when they were in the draft phase. These are updated from the previous 2008 and 2014 versions and reflect the changes in our knowledge and practice over the last 10 years. While there are many similarities, the astute reader will find distinct differences from the AUA Guidelines, which feature in a summary booklet released at the #AUA19 meeting in Chicago this spring.

    NICE does not comment on screening for prostate cancer so many of us continue to rely on our Guideline of Guidelines 2, which make pragmatic recommendations such as smart screening in well‐informed men who are at higher risk because of their family history. For staging, bone scan has not been replaced by prostate‐specific membrane antigen (PSMA)‐positron‐emission tomography/CT, and Lu‐PSMA theranostics is yet to become an option in castrate‐resistant disease as the international trials are not mature.

    Multiparametric MRI before prostate biopsy in men suitable for radical treatment is a new addition, based on the PROMIS 3 and PRECISION trials 1. This approach is thought to be cost‐effective through reducing the number of biopsies and side effects despite the initial added cost of MRI scanning. In Grade Group 1 and some low‐volume Grade Group 2 cancers, protocol‐based active surveillance is recommended provided the patients are well counselled and it has been discussed by a multidisciplinary team.

    To reduce variations in active surveillance, Prostate Cancer UK has carefully examined eight different guidelines and published a consensus statement for the benefit of our patients 4. We have already promoted this widely on social media and hope that our readers will use this practical tool in their clinics. We often find that some patients just cannot live with a cancer inside their body and seek surgery as a result, however small their tumour. Careful discussion about management options and their risks vs benefits 1 can help patients arrive at a pragmatic decision. The effect of a cancer diagnosis on patients’ minds should therefore not be underestimated and a trained psychologist should be available for appropriate counselling.

    NICE also recommends hypofractionated intensity‐modulated radiotherapy, if appropriate, in combination with androgen deprivation therapy (ADT) for localized disease, and methods of decreasing the side effects while increasing accuracy of radiation. As in 2014, robot‐assisted radical prostatectomy remains a surgical option in centres performing at least 150 of these procedures per year 1. These numbers are similar to those published from other health services such as Canada. One such very high‐volume centre is the Martini Clinic which has reported its comparison of open and robot‐assisted radical prostatectomy in >10 000 patients. The oncological and functional outcomes are no different, open surgery is quicker and there is less blood loss and shorter time to catheter removal after robotic surgery. Just like the randomized trial of the two techniques, this large series highlights that surgeon experience rather than the technique is more important for clinical outcomes 5. Finally, based on the STAMPEDE results, docetaxel is recommended for metastasis in addition to ADT and can be considered for high‐risk patients receiving ADT and radiotherapy6. NICE has also identified a number of important research questions which we hope will be answered by ongoing studies in coming years.
    [Emphasis mine]

    NICE Guidance – Prostate cancer: diagnosis and management [2019, Full Text]

    This guideline covers the diagnosis and management of prostate cancer in secondary care, including information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment. It also includes recommendations on follow‐up in primary care for people diagnosed with prostate cancer.

    Who is it for?
    • Healthcare professionals
    • Commissioners and providers of prostate cancer services
    • People with prostate cancer, their families and carers
    • Recommendations
    • People have the right to be involved in discussions and make informed decisions about their care, as described in your care (https://www.nice.org.uk/about/nice-c...bout-your-care).

    Making decisions using NICE guidelines (http://www.nice.org.uk/about/what-we...make-decisions) explains how we use words to show the strength (or certainty) of our recommendations, and has information about prescribing medicines (including off‐label use), professional guidelines, standards and laws (including on consent and mental capacity), and safeguarding.
    (See Full Text.) I didn't see mention of proton therapy. Googling it, it appears that the first full-power installations are currently being built in Britain. I would think care in the National Health Service affects treatment advice.
    Last edited by DjinTonic; 06-18-2019 at 05:07 PM.

  2. #2
    A lot of detail. I noticed what they advised against: HIFU and cryotherapy, except in a clinical trial, and the PCA3 and PHI tests.

    They also seemed to be against immediate radiation treatment (ART) when positive lymph nodes were found at RP.

    They are in favor of reducing IMRT to 20 sessions, and more reliance on MRIs.

    Much in common with USA guidelines. Thanks
    DOB: May 1944
    In Active Surveillance program at Johns Hopkins
    Strict protocol of tests, including PHI, DRE, MRI, and biopsy.
    Six biopsies from 2009 to 2019. Numbers 1, 2, and 5 were negative. Numbers 3,4, and 6 were positive with 5% Gleason(3+3) found. Last one was Precision Point transperineal.
    PSA has varied up and down from 3 to 10 over the years. Is 4.0 as of September 2019.
    Hopefully, I can remain untreated. So far, so good.


Similar Threads

  1. San Francisco T-Cell Lymphoma patient seminar June 8th, 2019
    By po18guy in forum Lymphoma - Hodgkin's and Non-Hodgkin's Lymphoma Forum
    Replies: 0
    Last Post: 05-24-2019, 02:20 PM
  2. Replies: 0
    Last Post: 05-20-2019, 01:10 PM
  3. Dr. Robert O. Hickman, 1927-2019
    By po18guy in forum Lymphoma - Hodgkin's and Non-Hodgkin's Lymphoma Forum
    Replies: 1
    Last Post: 04-12-2019, 09:54 AM
  4. Malignant Ascites: Diagnosis and Management
    By ddessert in forum Pancreatic Cancer Forum
    Replies: 0
    Last Post: 05-12-2015, 10:41 PM
  5. New advance in prostate cancer management
    By leo in forum Cancer News
    Replies: 0
    Last Post: 08-15-2005, 04:00 AM

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts